bud stock

Canbud Enters into Memorandum of Understanding for Psilocybin Producing Mushroom Research and Development

Canbud Distribution Corp. (CSE: CBDX) (FSE: CD0) (the "Corporation" or "Canbud") is pleased to announce that on September 3,2021 it has entered into a memorandum of understanding (the "MOU") with the College of Agriculture, Science and Education ("CASE"), establishing a business and research and development ("R&D") relationship between the parties. CASE is a tertiary educational institution located in Port Antonio, Jamaica, with a tripartite mandate of teaching, research, and outreach.

Under the terms of the MOU, Canbud and CASE formed a commercial relationship focused on the research and development of healing practices facilitated by psilocybin producing mushrooms, and the manufacture of consumer products from psilocybin mushrooms for health benefits. The MOU includes, among other things, provisions to reflect the following key agreements and understandings between the parties:

  • The term of the MOU commenced on September 3, 2021 and ends on August 22, 2022.
  • During the term Canbud will lease its existing mobile commercial facility to CASE at no cost for use in an R&D capacity and for commercial production, based on terms to be agreed separately.
  • Canbud will provide to CASE up to $10,000 of funding for a mutually approved R&D program intended to evaluate the potential uses of psilocybin and other psychedelic properties within mushrooms. Any results of these research will be made available to Canbud for its exclusive use.
  • If and when CASE commences commercial production, the parties intend to negotiate and enter into a separate agreement, which would provide, among other things, that Canbud would have right of first refusal to acquire any commercial production, and at least 50% of commercial production would be purchased by Canbud on agreed terms. CASE would have the ability to sell any production not purchased by Canbud, with economics to be shared by CASE and Canbud on terms to be agreed by the parties.
  • The respective ownership rights to any intellectual property are to be agreed by the parties prior to any commercialization or monetization of these rights.
  • CASE would seek to acquire all the necessary research licenses to facilitate the exportation of mushrooms to both Canada and the United States of America once commercial production plans are finalized, subject to applicable laws.
  • CASE will manage and operate the research laboratory.

Steve Singh, CEO of Canbud, notes "We are extremely pleased to enter into research partnership with CASE that is intended to help enable Canbud to undertake a scientific approach to understanding the medicinal properties of specific mushrooms and potentially replicate the cultivation of those spores on a commercial scale in the future."

About Canbud Distribution Corp.
Canbud is a science and technology health and wellness company carrying on business in the plant based, psychedelic pharmaceutical and non-psychedelic nutraceutical, and hemp cannabinoid (CBD) vertical markets.

Notice Regarding Forward-Looking Information
Certain statements in this news release related to the Corporation are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward- looking words such as "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the future operations of the Corporation, the perceived opportunities in the psilocybin-based medical and nutraceutical markets globally, the potential to launch mushroom-based and psilocybin-containing products within enabling current and anticipated legal frameworks globally, the success of the joint R&D efforts of the Corporation and CASE, the benefits of the MOU, the intention to enter into subsequent agreements and commercial arrangements, any future commercial production, and the obtaining of all such licences, registrations and consents as may be required from regulatory and governmental authorities regulating to the products and activities referred to in this news release. There are numerous risks and uncertainties that could cause actual results and the Corporation's plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Corporation does not intend to update these forward-looking statements. The Corporation makes no medical, treatment or health benefit claims about the Corporation's proposed products.

Health Canada, the U.S. Food and Drug Administration, or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products have not been confirmed by approved research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Corporation has not conducted clinical trials for the use of its proposed products. If the Corporation cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Corporation's performance and operations.

For further information please contact:
Robert Tjandra, COO
(416) 847-7312


To view the source version of this press release, please visit

News Provided by Newsfile via QuoteMedia

agricultural engineers working in field

Agriculture Market Forecast: Top Trends That Will Affect Potash and Phosphate in 2023

Fertilizer prices surged to new heights in 2022, continuing a trend that began in 2021. The toll of war, rising gas costs, Chinese export issues and high crop prices pushed both phosphate and potash to record levels in April.

“Agricultural prices reached record highs in Q2 2022 as grain prices shot up in the aftermath of the war in Ukraine — both Russia and Ukraine are key global grain producers,” FocusEconomics' latest commodities outlook reads.

However, during the second half of 2022, demand destruction resulted in a 10 to 40 percent decline in consumption for both phosphate and potash, which pushed values lower.

Keep reading...Show less
graphic that says ASX over blurred digital charts

ASX Agriculture Stocks: 5 Biggest Companies in 2023

From crop technology to packaging and distribution, the agricultural industry is one of the largest and most important industries in the world.

The price of fertilizer has jumped this past year due to the economic sanctions on Russia and Belarus as well as restrictions on exporting to China. With it, the prices of potash and phosphate have jumped as well. The agriculture sector has already been faced with environmental challenges of soil and biodiversity erosion as climate change, Russia’s invasion of Ukraine has only amplified this.

With Ukraine being a major exporter of wheat, corn, and seed oils, the rest of the world has been forced to adapt as the country has been under the distress of the Russian invasion in February 2022. Additionally, the heightened focus on defeating climate change has encouraged many companies to switch gears to clean energy and the implementation of greener technologies to help create a sustainable future.

Keep reading...Show less
International Zeolite and CoTec Holdings Announce Strategic Alliance

International Zeolite and CoTec Holdings Announce Strategic Alliance

CoTec Holdings Making Anchor Investment to Accelerate Commercialization of International Zeolite's Revolutionary Proprietary NEREA(R) Fertilizer Technology

International Zeolite Corp. (TSXV: IZ) (OTCQB: IZCFF) (FSE: ZEON) ("IZ") and CoTec Holdings Corp. (TSXV: CTH) ("CoTec") are pleased to announce that CoTec has agreed to make a $2 million strategic investment in IZ to support its go-to-market activities in the agricultural and green tech segments.

CoTec and IZ share similar visions and objectives and are focused on creating a portfolio of green disruptive technologies that are high-margin, eco-friendly and deliver reductions in carbon emissions. The investment from CoTec is expected to fast track IZ's ability to move rapidly to full commercialization, marketing and sales capabilities for its disruptive agricultural products and solutions. The funding will support the construction of IZ's first NEREA® production facility to be in Ontario, Canada with an expected completion date of March 2023. In addition to its financial investment, CoTec will support IZ through the involvement of its management team, who collectively have extensive global reach and expertise in green technologies.

Keep reading...Show less
kangaroos in front of the sunrise

Investing in Agriculture in Australia (Updated 2022)

Investing in the Australian agriculture sector could prove to be a lucrative decision for investors.

Higher-than-average rainfall has led to a record-breaking summer grain crop in Australia. This, paired with increased prices for grain, cattle and canola caused by the Russian-Ukrainian conflict spells a strong outlook for the Australian agriculture sector.

Investors who are interested in capitalising on the well-established Australian agricultural sector should consider the key factors and players involved.

Keep reading...Show less
Billy Goat

Billy Goat Announces Grant of Restricted Share Units and Option

Billy Goat Brands Ltd. (the "Company" or "Billy Goat") (CSE: GOAT), is pleased to announce that it has granted an aggregate of 11,500,000 restricted share units ("RSUs") to certain arm's-length consultants, and an aggregate of 1,000,000 incentive stock options ("Options") to directors of the Company to purchase up to 1,000,000 common shares of the Company at a price of $0.05 per common share for a period of five years from grant, as compensation for continuing services rendered to the Company.

The RSUs and the Options will vest four months and one day from the date of issuance, subject to earlier vesting in the event of a change of control and subject to the policies of the Canadian Securities Exchange.

Keep reading...Show less
Billy Goat

Billy Goat Expands Investment Thesis and Capital Deployment Mandates

Billy Goat Brands Ltd. (the "Company" or "GOAT") (CSE: GOAT), is pleased to announce the Company will look to expand its capital deployment mandate and diversify its investment portfolio to include accretive holdings in new market sectors, including the following:

  • Industrials;
  • Defence Technologies;
  • Electrification;
  • Critical Commodities;
  • Energy; and,
  • ETM Extraction.

The above stated verticals are expected to provide GOAT with exposure to historically anti-inflationary investments which mitigate reliance on unstable international supply chains. GOAT's management team and investment committee expect to retain exposure to its current plant-based products holdings. The Company has not yet identified potential investments in these sectors, and will advise shareholders as new opportunities are pursued.

Keep reading...Show less

Latest Press Releases

Related News